Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans

被引:100
作者
Picardi, Marco
De Renzo, Amalia
Pane, Fabrizio
Nicolai, Emanuele
Pacelli, Roberto
Salvatore, Marco
Rotoli, Bruno
机构
[1] Univ Naples Federico II, Sch Med, Dept Biochem & Med Biotechnol, Naples, Italy
[2] Ist Ric Diagnost Nucl, SDN, Naples, Italy
[3] Univ Naples Federico II, Sch Med, Dept Biomorpholog & Funct Sci, Naples, Italy
关键词
Hodgkin's lymphoma; bulky disease; radiotherapy; FDG-PET;
D O I
10.1080/10428190701559140
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed at evaluating the role of consolidation radiation in a setting of Hodgkin's lymphoma (HL) patients, using event-free survival (EFS) as end point. Among 260 patients treated with induction chemotherapy for bulky HL, 160 patients achieved negative residual masses at 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scans. They were randomly divided into two well-matched groups to receive either 32 Gy radiotherapy to bulky area or no further therapy. At a median follow-up of 40 months, histology showed a malignancy in 14% of patients in the chemotherapy-only group (HL, 11 patients) and in 14% of patients in the chemotherapy + radiotherapy group (HL, 2 patients; carcinoma in previously irradiated area, 1 patient) (P = 0.03). All the relapses in the chemotherapy-only group involved the bulky site and the contiguous nodal regions. Thus, the overall diagnostic accuracy of FDG-PET to exclude future relapses in the patients nonprotected by radiotherapy was 86% with a false-negative rate of 14%. Our study suggests that the addition of irradiation helps improve EFS in HL patients with post-chemotherapy FDG-PET-negative residual masses.
引用
收藏
页码:1721 / 1727
页数:7
相关论文
共 18 条
[1]   Involved-field radiotherapy for advanced Hodgkin's lymphoma [J].
Aleman, BMP ;
Raemaekers, JMM ;
Tirelli, U ;
Bortolus, R ;
van't Veer, MB ;
Lybeert, MLM ;
Keuning, JJ ;
Carde, P ;
Girinsky, T ;
van der Maazen, RWM ;
Tomsic, R ;
Vovk, M ;
van Hoof, A ;
Demeestere, G ;
Lugtenburg, PJ ;
Thomas, J ;
Schroyens, W ;
De Boeck, K ;
Baars, JW ;
Kluin-Nelemans, JC ;
Carrie, C ;
Aoudjhane, M ;
Bron, D ;
Eghbali, H ;
Smit, WGJM ;
Meerwaldt, JH ;
Hagenbeek, A ;
Pinna, A ;
Henry-Amar, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2396-2406
[2]   Long-term cause-specific mortality of patients treated for Hodgkin's disease [J].
Aleman, BMP ;
van den Belt-Dusebout, AW ;
Klokman, WJ ;
van't Veer, MB ;
Bartelink, H ;
van Leeuwen, FE .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3431-3439
[3]   RESIDUAL MASS IN LYMPHOMA MAY NOT BE RESIDUAL DISEASE [J].
CANELLOS, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) :931-933
[4]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[5]   Chemotherapy or combined modality treatment: The optimal treatment for Hodgkin's disease [J].
Diehl, V .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :15-18
[6]   Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].
Diehl, V ;
Franklin, J ;
Pfreundschuh, M ;
Lathan, B ;
Paulus, U ;
Hasenclever, D ;
Tesch, H ;
Herrmann, R ;
Dörken, B ;
Müller-Hermelink, H ;
Dühmke, E ;
Loeffler, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395
[7]  
Fermé C, 2000, BLOOD, V95, P2246
[8]   Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease:: Mature results of a prospective clinical trial [J].
Horning, SJ ;
Hoppe, RT ;
Breslin, S ;
Bartlett, NL ;
Brown, BW ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :630-637
[9]   A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma [J].
Isasi, CR ;
Lu, P ;
Blaufox, MD .
CANCER, 2005, 104 (05) :1066-1074
[10]   Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging [J].
Jerusalem, G ;
Beguin, Y ;
Fassotte, MF ;
Najjar, F ;
Paulus, P ;
Rigo, P ;
Fillet, G .
BLOOD, 1999, 94 (02) :429-433